Fisher & Paykel HealthcareFSPKF +9.59%90 ROC (Joel Greenblatt) % is 43.48% as of Mar. 2026, which is 2% below its 10-year median of 44.55. GuruFocus rates FSPKF with a GF Scoreâ„¢ of 90/100 and a GF Valueâ„¢ of $25.21 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 840 Medical Devices & Instruments companies, Fisher & Paykel Healthcare ranks better than 85.36% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Fisher & Paykel Healthcare's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 43.48%.
The historical rank and industry rank for Fisher & Paykel Healthcare's ROC (Joel Greenblatt) % or its related term are showing as below:
FSPKF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 16.18 Med: 44.55 Max: 78.69
Current: 40.18
During the past 13 years, Fisher & Paykel Healthcare's highest ROC (Joel Greenblatt) % was 78.69%. The lowest was 16.18%. And the median was 44.55%.
FSPKF's ROC (Joel Greenblatt) % is ranked better than 85.36% of 840
companies
in the Medical Devices & Instruments industry
Industry Median: 4.035
vs FSPKF: 40.18
Fisher & Paykel Healthcare's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -12.70% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FSPKF vs ISRG, BDX, MDLN: ROC (Joel Greenblatt) % Comparison
For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fisher & Paykel Healthcare ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Fisher & Paykel Healthcare's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 43.48% mean?
Fisher & Paykel Healthcare (FSPKF) has a ROC (Joel Greenblatt) % of 43.48% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Fisher & Paykel Healthcare and its competitors. This is near median its historical median of 44.55. Over the past decade, Fisher & Paykel Healthcare's ROC (Joel Greenblatt) % has ranged from 16.18 to 78.69. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #123 out of 840 companies in the Medical Devices & Instruments industry, placing it in the top 14.6%.
Is Fisher & Paykel Healthcare's ROC (Joel Greenblatt) % too high?
Fisher & Paykel Healthcare's current ROC (Joel Greenblatt) % of 43.48% is near median its 10-year median of 44.55. Over the past 10 years, this metric has ranged from a low of 16.18 to a high of 78.69. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.04. Fisher & Paykel Healthcare's value of 43.48% is 977.6% above this industry median. Based on the distribution chart, Fisher & Paykel Healthcare ranks #123 out of 840 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Fisher & Paykel Healthcare has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's ROC (Joel Greenblatt) % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #123 out of 840 companies for ROC (Joel Greenblatt) %. This places Fisher & Paykel Healthcare in the top 15% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 4.04. Fisher & Paykel Healthcare's value of 43.48% is 977.6% above this benchmark. Historically, Fisher & Paykel Healthcare's own ROC (Joel Greenblatt) % has ranged from 16.18 to 78.69 over the past decade. While the company's 10-year median is 44.55 vs. the industry median of 4.04, Fisher & Paykel Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.04, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fisher & Paykel Healthcare's current ROC (Joel Greenblatt) % of 43.48% is 977.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Fisher & Paykel Healthcare and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fisher & Paykel Healthcare's current ROC (Joel Greenblatt) % is 43.48%, which is near median its own 10-year median of 44.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (FSPKF) is currently considered Modestly Undervalued. The stock's GF Value™ is $25.21, compared to a current price of $22.52 — trading 10.7% below its estimated fair value. The current ROC (Joel Greenblatt) % is 43.48%, which is near median its 10-year median of 44.55 and 977.6% above the Medical Devices & Instruments industry median of 4.04. Fisher & Paykel Healthcare's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Fisher & Paykel Healthcare (FSPKF), the current ROC (Joel Greenblatt) % is 43.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fisher & Paykel Healthcare (FSPKF) Overvalued in 2026?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued.
The current stock price of $22.52 is trading 10.7% below its estimated GF Value™ of $25.21.
GuruFocus considers Fisher & Paykel Healthcare to be Modestly Undervalued.
Key valuation signals for FSPKF:
ROC (Joel Greenblatt) %: 43.48% (near median its 10-year median of 44.55)
GF Value™: $25.21 vs. price of $22.52 (10.7% below fair value)
Industry Position: 977.6% above the Medical Devices & Instruments median (#123 of 840)
No single metric tells the full story. See the FSPKF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
90GF Score
Get the complete analysis for FSPKF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSPKF has been successfully added to your 
